Th1/Th2 cytokine profile in childhood-onset systemic lupus erythematosus

Cytokine

Volumn 61, Issue 3, 2013, Pages 785-791

  Postal, Mariana ^a   Peliçari, Karina Oliveira ^a   Sinicato, Nailú Angélica ^a   Marini, Roberto ^a   Costallat, Lilian Tereza Lavras ^a   Appenzeller, Simone ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Childhood onset systemic lupus erythematosus; Interferon gamma (IFN ); Interleukin (IL) 5, 6, 10, and 12; SLEDAI; Tumor necrosis factor alpha (TNF )

Indexed keywords

CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 6; PREDNISONE; TH1 CYTOKINE; TH2 CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CHILD; CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST DEGREE RELATIVE; HUMAN; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGE OF ONSET; BRAZIL; CASE-CONTROL STUDIES; CHILD; CYTOKINES; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOASSAY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; TH1 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 84875379460     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.11.023     Document Type: Article

References (86)

1. Papadimitraki E.D., Isenberg D.A. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 2009, 5:391-403.
2. Klein-Gitelman M., Reiff A., Silverman E.D. Systemic lupus erythematosus in childhood. Rheum Dis Clin N Am 2002, 28:561-577.
3. Stichweh D., Arce E., Pascual V. Update on pediatric systemic lupus erythematosus. Curr Opin Rheumatol 2004, 16:577-587.
4. Tucker L.B., Menon S., Schaller J.G., Isenberg D.A. Adult and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology and outcome. Br J Rheum 1995, 34:866-872.
5. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006, 15:308-318.
6. Malleson P.N., Fung M.Y., Rosenberg A.M. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996, 23:1981-1987.
7. McCarty D.J., Manzi S., Medsger T.A., Ramsey-Goldman R., LaPorte R.E., Kwoh C.K. Incidence of systemic lupus erythematosus Race and gender differences. Arthritis Rheum 1995, 38:1260-1270.
8. Mina R., Brunner H.I. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?. Rheum Dis Clin North Am. 2010, 36:53-80.
9. Font J., Cervera R., Espinosa G., Pallarés L., Ramos-Casals M., Jiménez S., et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis 1998, 57:456-459.
10. Hoffman I.E., Lauwerys B.R., De Keyser F., Huizinga T.W., Isenberg D., Cebecauer L., et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009, 68:412-415.
11. Sibbitt W.L., Brandt J.R., Johnson C.R., Maldonado M.E., Patel S.R., Ford C.C., et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002, 29:1536-1542.
12. Carreno L., Lopez-Longo F.J., Monteagudo I., Rodríguez-Mahou M., Bascones M., González C.M., et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 1999, 8:287-292.
13. Brunner H.I., Gladman D.D., Ibanez D., Urowitz M.D., Silverman E.D. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008, 58:556-562.
14. Tucker L.B., Menon S., Schaller J.G., Isenberg D.A. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995, 34:866-872.
15. Hersh A.O., von Scheven E., Yazdany J., Panopalis P., Trupin L., Julian L., et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009, 61:13-20.
16. Appenzeller S., Marini R., Costallat L.T. Damage did not independently influence mortality in childhood systemic lupus erythematosus. Rheumatol Int. 2005, 25:619-624.
17. von Scheven E., Bakkaloglu A. What's new in paediatric SLE?. Best Pract Res Clin Rheumatol 2009, 23:699-708.
18. Yap D.Y., Lai K.N. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010, 2010:365083.
19. Gómez D., Correa P.A., Gómez L.M., Cadena J., Molina J.F., Anaya J.M. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum 2004, 33:404-413.
20. Sabry A., Elbasyouni S.R., Sheashaa H.A., Alhusseini A.A., Mahmoud K., George S.K., et al. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int Urol Nephrol 2006, 38:731-737.
21. Mellor-Pita S., Citores M.J., Castejon R., Yebra-Bango M., Tutor-Ureta P., Rosado S., et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 2009, 76:261-270.
22. Park Y.B., Lee S.K., Kim D.S., Lee J., Lee C.H., Song C.H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998, 16:283-288.
23. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
24. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42:599-608.
25. Harris E.N., Gharavi A.E., Patel S.P., Hughes G.R. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987, 68:215-222.
26. Brandt J.T., Triplett D.A., Alving B., Scharrer I. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995, 74:1185-1190.
27. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
28. Yee C.S., Farewell V.T., Isenberg D.A., Griffiths B., Teh L.S., Bruce I.N., et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011, 50:982-988.
29. Gladman D.D., Urowitz M.B., Goldsmith C.H., Fortin P., Ginzler E., Gordon C., et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:809-813.
30. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
31. Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988, 56:893-897.
32. Leroux-Roels G., Offner F., Philippe J., Vermeulen A. Influence of blood collecting systems on concentrations of tumor necrosis factor in serum and plasma. Clin Chem 1988, 134:2373-2374.
33. Galley H.F., Webster N.R. The immuno-inflammatory cascade. Br J Anaesth 1996, 77:11-16.
34. Wozniacka A., Lesiak A., Narbutt J., McCauliffe D.P., Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006, 15:268-275.
35. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
36. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998, 70:83-243.
37. Farrar M.A., Schreiber R.D. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993, 11:571-611.
38. Joseph A., Brasington R., Kahl L., Ranganathan P., Cheng T.P., Atkinson J. Immunologic rheumatic disorders. J Allergy Clin Immunol 2010, 125:S204-S215.
39. Kollias G., Douni E., Kassiotis G., Kontoyiannis D. The function of tumor necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 1999, 58:132-139.
40. Bradley J.R. TNF-mediated inflammatory disease. J Pathol 2008, 214:149-160.
41. Wen X., Zhang D., Kikuchi Y., Jiang Y., Nakamura K., Xiu Y., et al. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur J Immunol 2004, 34:2740-2749.
42. Sun K.H., Yu C.L., Tang S.J., Sun G.H. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000, 99:352-360.
43. Battaglia M., Gianfrani C., Gregori S., Roncarolo M.G. IL-10-producing T regulatory type 1 cells and oral tolerance. Ann NY Acad Sci 2004, 1029:142-153.
44. Gerli R., Nocentini G., Alunno A., Bocci E.B., Bianchini R., Bistoni O., et al. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009, 8:426-430.
45. Roncarolo M.G., Bacchetta R., Bordignon C., Narula S., Levings M.K. Type 1 T regulatory cells. Immunol Rev 2001, 182:68-79.
46. Pot C., Apetoh L., Kuchroo V.K. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol 2011, 23:202-208.
47. Groux H., Bigler M., de Vries J.E., Roncarolo M.G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996, 184:19-29.
48. Al-Mutairi S., Al-Awadhi A., Raghupathy R., Al-Khawari H., Sada P., Al-Herz A., et al. Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile. Rheumatol Int 2007, 27:621-630.
49. Sabry A.A., Elbasyouni S.R., Kalil A.M., Abdel-Rahim M., Mohsen T., Sleem A. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus. Nephrology (Carlton) 2006, 11:329-335.
50. Sabry A., Sheashaa H., El-Husseini A., Mahmoud K., Eldahshan K.F., George S.K., et al. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006, 35:148-153.
51. Gabay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J.M., et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997, 24:303-308.
52. Mahmoud R.A., El-Gendi H.I., Ahmed H.H. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem 2005, 38:134-141.
53. Jones B.M., Liu T., Wong R.W. Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity 1999, 31:117-124.
54. Studnicka-Bencke A., Steiner G., Petera P., Smolen J.S. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996, 35:1067-1074.
55. Masutani K., Akahoshi M., Tsuruya K., Tokumoto M., Ninomiya T., Kohsaka T., et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001, 44:2097-2106.
56. Gigante A., Gasperini M.L., Afeltra A., Barbano B., Margiotta D., Cianci R., et al. Cytokines expression in SLE nephritis. Eur Rev Med Pharmacol Sci 2011, 15:15-24.
57. Gloor J.M. Lupus nephritis in children. Lupus 1998, 7:639-643.
58. Ihm C.G., Park J.K., Hong S.P., Lee T.W., Cho B.S., Kim M.J. Circulating factors in sera or peripheral blood mononuclear cells in patients with membranous nephropathy or diabetic nephropathy. J Korean Med Sci 1997, 12:539-544.
59. Lionaki S., Siamopoulos K., Theodorou I., Papadimitraki E., Bertsias G., Boumpas D., et al. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 2009, 24:2144-2150.
60. Dean G.S., Tyrrell-Price J., Crawley E., Isenberg D.A. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000, 59:243-251.
61. Aringer M., Smolen J.S. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008, 7:411-419.
62. Aringer M., Smolen J.S. Tumor necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004, 13:344-347.
63. Aringer M., Steiner G., Graninger W.B., Höfler E., Steiner C.W., Smolen J.S. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 2007, 56:274-279.
64. Zhu L.J., Yang X., Yu X.Q. Anti-TNF-alpha therapies in systemic lupus erythematosus. Biomed Biotechnol 2010, 2010:465898.
65. Murdaca G., Colombo B.M., Puppo F. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmune Rev 2011, 11:56-60.
66. Mageed R.A., Isenberg D.A. Tumors necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus 2002, 11:850-855.
67. Aringer M., Smolen J.S. Therapeutic blockade on TNF in patients with SLE-promising or crazy?. Autoimmune Rev 2012, 11:321-325.
68. Tucci M., Lombardi L., Richards H.B., Dammacco F., Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 2008, 154:247-254.
69. Nagai T., Yanagida T., Hirohata S. Anti-ribosomal P protein antibody induces Th1 responses by enhancing the production of IL-12 in activated monocytes. Mod Rheumatol 2011, 21:57-62.
70. Hsieh C.C., Lin B.F. Dietary factors regulate cytokines in murine models of systemic lupus erythematosus. Autoimmun Rev. 2011, 11:22-27.
71. López P., Gómez J., Prado C., Gutiérrez C., Suárez A. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 2008, 35:1559-1566.
72. Suárez A., López P., Mozo L., Gutiérrez C. Differential effect of IL10 and TNF-α genotypes on determining susceptibility to discoid and systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1605-1610.
73. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001, 11:203-208.
74. Tuglu C., Kara S.H., Caliyurt O., Vardar E., Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003, 170:429-433.
75. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
76. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001, 11:372-377.
77. Khairova R.A., Machado-Vieira R., Du J., Manji H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009, 12:561-578.
78. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology 2012, 62:419-426.
79. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010, 128:519-548.
80. Yoon H.K., Kim Y.K., Lee H.J. Role of cytokines in atypical depression. Nord J Psychiatry 2012, 66:183-188.
81. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008, 23:421-429.
82. Kim Y.K., Na K.S., Shin K.H., Jung H.Y., Choi S.H., Kim J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1044-1053.
83. Alarcón G.S., McGwin G., Bertoli A.M., Fessler B.J., Calvo-Alén J., Bastian H.M., et al. LUMINA study group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007, 66:1168-1172.
84. Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immunol 2007, 8:492-502.
85. Niewold T.B., Adler J.E., Glenn S.B., Lehman T.J., Harley J.B., Crow M.K. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008, 58:2113-2119.
86. Scofield R.H., Bruner G.R., Harley J.B., Namjou B. Autoimmune thyroid disease is associated with a diagnosis of secondary Sjogren's syndrome in familial systemic lupus. Ann Rheum Dis 2007, 66:410-413.